Progression free
Showing 1 - 25 of >10,000
Metastatic Prostate Cancer Trial (Darolutamide, Radium-223)
Not yet recruiting
- Metastatic Prostate Cancer
- (no location specified)
Mar 6, 2023
Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant
Completed
- The Primary Study Metric is Progression-free Survival (PFS)
- (no location specified)
Jun 28, 2023
Progression-free Survival Trial (Sovalteinib Solutumab Tegeo)
Not yet recruiting
- Progression-free Survival
- Sovalteinib Solutumab Tegeo
- (no location specified)
Jul 24, 2023
Overall Survival, Progression-free Survival, Cost Trial (Microwave Ablation)
Completed
- Overall Survival
- +2 more
- Microwave Ablation
- (no location specified)
Apr 1, 2023
Progression Free Survival(PFS) Trial (Toposide capsules combined with anrotinib and Emvolizumab group)
Not yet recruiting
- Progression Free Survival(PFS)
- Toposide capsules combined with anrotinib and Emvolizumab group
- (no location specified)
Jan 13, 2023
Meningioma, Meningioma Atypical, Anaplastic Meningioma Trial in Rome (Biological biomarker assessment)
Recruiting
- Meningioma
- +2 more
- Biological biomarker assessment
-
Rome, ItalyFondazione Policlinico Universitario A. Gemelli IRCCS
Mar 29, 2023
Pancreatic Cancer, Thromboembolism Trial in Athens (Innohep, Chemotherapy: Gemcitabine + Nab-Paclitaxel)
Recruiting
- Pancreatic Cancer
- Thromboembolism
- Innohep
- Chemotherapy: Gemcitabine + Nab-Paclitaxel
-
Athens, Attiki, Greece
- +1 more
Mar 28, 2022
Bladder Cancer, Bladder Urothelial Carcinoma Trial in Toronto (re-TURBT, 6 weeks BCG instillation)
Terminated
- Bladder Cancer
- Bladder Urothelial Carcinoma
- re-TURBT
- 6 weeks BCG instillation
-
Toronto, Ontario, CanadaUniversity Health Network
Apr 12, 2022
Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality
Recruiting
- Breast Cancer Stage IV
- comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
-
Mansoura, Dakahlia, EgyptOncology center mansoura university
Jan 1, 2023
Progression Free Survival, Overall Survival, Maintenance Trial (Ixazomib DX/Lenalidomide DX)
Not yet recruiting
- Progression Free Survival
- +2 more
- Ixazomib DX/Lenalidomide DX
- (no location specified)
Jul 27, 2022
free Survival and Evaluate Participant Experience for Metastatic
Active, not recruiting
- Anaplastic Lymphoma Kinase-positive
- Carcinoma Non-small-cell Lung
- Brigatinib
- +4 more
-
Maynard, MassachusettsEmpiraMed, Inc.
Feb 28, 2022
Glioblastoma Trial in Toronto (Exercise)
Completed
- Glioblastoma
- Exercise
-
Toronto, Ontario, CanadaPrincess Margaret Hospital, University Health Network
Apr 13, 2022
NSCLC Trial in Rozzano (Pemetrexed/Carboplatin, Gemcitabine)
Terminated
- NSCLC
-
Rozzano, Milan, ItalyIstituto Clinco Humanitas
Sep 8, 2022
Chromosomal Instability in Ovarian Cancer
Recruiting
- Epithelial Ovarian Cancer
- +7 more
- Testing for chromosomal instability (CIN)
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Pancreatic Adenocarcinoma Trial in Philadelphia (Niraparib + Nivolumab, Niraparib + Ipilimumab)
Active, not recruiting
- Pancreatic Adenocarcinoma
- Niraparib + Nivolumab
- Niraparib + Ipilimumab
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania, Abramson Cancer Center
Mar 23, 2022
Metabolic Syndrome, Pregnant Women, Birth Outcomes Trial in Jimma (Exposure, Non exposure)
Recruiting
- Metabolic Syndrome
- +4 more
- Exposure
- Non exposure
-
Jimma, EthiopiaJimma University Medical Center
Jun 28, 2023
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Recruiting
- Immune Checkpoint Inhibitors
- +9 more
- Radiotherapy for targeted lesions and PD-1 antibody
-
Beijing, Beijing, ChinaLei Li
Apr 1, 2022
Multiple Myeloma Trial in Little Rock (Carfilzomib, Thalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +11 more
-
Little Rock, ArkansasUniversity of Arkansas for Medical Sciences
Sep 1, 2022
Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival Trial in Wuhan (Surufatinib)
Recruiting
- Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
-
Wuhan, Hubei, ChinaZhongnan Hopital of Wuhan University
Mar 8, 2022
HRD and Resistance to PAPPi in EOC Patients
Recruiting
- Epithelial Ovarian Cancer
- +6 more
- Testing of homologous recombination deficiency
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Colorectal Cancer, Chinese Herbal Medicine, Progression-free Survival Trial in China (Brucea javanica oil emulsion injection,
Recruiting
- Colorectal Cancer
- +3 more
- Brucea javanica oil emulsion injection
- The best supportive treatment
-
Guangzhou, Guangdong, China
- +3 more
Jun 1, 2023
Colorectal Cancer, Oligometastatic Disease Trial in Australia (Local Ablative Therapy, Standard first-line systemic treatment)
Recruiting
- Colorectal Cancer
- Oligometastatic Disease
- Local Ablative Therapy
- Standard first-line systemic treatment
-
Albury, New South Wales, Australia
- +8 more
May 15, 2023
Waldenstrom's Disease, Prognostic Index Trial in France
Not yet recruiting
- Waldenstrom's Disease
- Prognostic Index
-
Amiens, France
- +14 more
Jun 12, 2023
Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant Trial in Hangzhou (Imatinib)
Recruiting
- Progression-free Survival
- +2 more
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 9, 2021
Metastatic Colorectal Cancer Trial in Marseille (Oncogramme results available, Oncogramme results unavailable)
Not yet recruiting
- Metastatic Colorectal Cancer
- Oncogramme results available
- Oncogramme results unavailable
-
Marseille, FranceHôpital Saint Joseph Marseille
Mar 18, 2022